Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Adaptive Hybrid Control Design for Comparative Clinical Trials with Historical Control Data

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

Incorporating Historical Information to Improve Phase I Clinical Trials

A Bayesian Response-Adaptive Covariate-Balanced Randomization Design with Application to A Leukemia Clinical Trial

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

Case weighted power priors for hybrid control analyses with time-to-event data

Statistical Inference of Adaptive Randomized Clinical Trials for Personalized Medicine

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

A Causal Inference Framework for Leveraging External Controls in Hybrid Trials

Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints

BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

PAM-HC: A Bayesian Nonparametric Construction of Hybrid Control for Randomized Clinical Trials Using External Data

Evaluation of the Fill-it-up-design to use historical control data in randomized clinical trials with two arm parallel group design

Enhancing Statistical Validity and Power in Hybrid Controlled Trials: A Randomization Inference Approach with Conformal Selective Borrowing

Matching within a hybrid RCT/RWD: framework on associated causal estimands

A matching design for augmenting a randomized clinical trial with external control

Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations

Weighting Based Approaches to Borrowing Historical Controls for Indirect comparison for Time-to-Event Data with a Cure Fraction